Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug

Scabies remains one of the most common parasitic skin diseases worldwide and continues to pose a substantial clinical and public health burden despite the availability of effective acaricidal treatments. Over the past decade, increasing reports of treatment failure following topical permethrin have reignited the debate on first-line therapy for scabies. While true acaricide resistance has been proposed as a possible explanation, current evidence remains inconclusive, and many apparent failures are more likely attributable to pseudo-resistance, including incorrect application, poor adherence, reinfestation, untreated contacts, or persistent post-scabetic symptoms. This renewed focus on the relative merits of topical permethrin and oral ivermectin has stimulated important discussions but may also have shifted attention away from the broader determinants of therapeutic success. In this Perspective, we argue that pharmacological efficacy alone does not adequately explain treatment success in routine clinical practice. Factors such as adherence, correct application of topical therapy, management of close contacts, reinfestation, persistent post-scabetic symptoms, and the epidemiological context frequently influence outcomes as much as the intrinsic activity of the acaricidal agent. Consequently, treatment failure often reflects shortcomings in the overall management process rather than true drug failure. We propose that future therapeutic decision-making should move beyond the traditional topical-versus-oral treatment debate toward a precision-based approach to scabies management. This framework encourages clinicians to individualize treatment strategies according to three complementary domains: patient characteristics, disease presentation, and epidemiological setting. Rather than replacing existing guidelines, this approach seeks to optimize their application in real-world practice by integrating pharmacological evidence with patient-centred care and transmission control. Reframing first-line therapy in this way may improve both individual outcomes and broader public health interventions.

Authors

Institutions

Publication Details

Journal
Medicines
Published
2026-11-20
DOI
https://doi.org/10.3390/medicines13040034
Primary Topic
Dermatological diseases and infestations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug

Angelo Valerio Marzano, Gianluca Nazzaro, Gianluca Tavoletti, Andrea Malgesini
2 links
Medicines
Dermatological diseases and infestations
article

Rethinking Pharmacological Management of Scabies: Beyond the First-Line Drug

Angelo Valerio Marzano, Gianluca Nazzaro, Gianluca Tavoletti, Andrea Malgesini
article en

Abstract

Scabies remains one of the most common parasitic skin diseases worldwide and continues to pose a substantial clinical and public health burden despite the availability of effective acaricidal treatments. Over the past decade, increasing reports of treatment failure following topical permethrin have reignited the debate on first-line therapy for scabies. While true acaricide resistance has been proposed as a possible explanation, current evidence remains inconclusive, and many apparent failures are more likely attributable to pseudo-resistance, including incorrect application, poor adherence, reinfestation, untreated contacts, or persistent post-scabetic symptoms. This renewed focus on the relative merits of topical permethrin and oral ivermectin has stimulated important discussions but may also have shifted attention away from the broader determinants of therapeutic success. In this Perspective, we argue that pharmacological efficacy alone does not adequately explain treatment success in routine clinical practice. Factors such as adherence, correct application of topical therapy, management of close contacts, reinfestation, persistent post-scabetic symptoms, and the epidemiological context frequently influence outcomes as much as the intrinsic activity of the acaricidal agent. Consequently, treatment failure often reflects shortcomings in the overall management process rather than true drug failure. We propose that future therapeutic decision-making should move beyond the traditional topical-versus-oral treatment debate toward a precision-based approach to scabies management. This framework encourages clinicians to individualize treatment strategies according to three complementary domains: patient characteristics, disease presentation, and epidemiological setting. Rather than replacing existing guidelines, this approach seeks to optimize their application in real-world practice by integrating pharmacological evidence with patient-centred care and transmission control. Reframing first-line therapy in this way may improve both individual outcomes and broader public health interventions.

MedicinesVol. 13(4)
University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Good health and well-being
Dermatological diseases and infestations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon